scholarly journals Analysis of prognostic factors in diffuse large B-cell lymphoma associated with rheumatic diseases

2021 ◽  
Vol 8 (1) ◽  
pp. e000561
Author(s):  
Vadim Gorodetskiy ◽  
Natalya Probatova ◽  
Tatiana Obukhova ◽  
Vladimir Vasilyev
Keyword(s):  
Prognostic Factors ◽  
B Cell ◽  
Rheumatic Diseases ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Large B Cell Lymphoma ◽  
Large B Cell ◽  
Sjögren‘S Syndrome

ObjectiveThe risk of developing diffuse large B-cell lymphoma (DLBCL) is increased in many rheumatic diseases (RDs). It is possible that RD-associated DLBCL is a distinct subset within the category of ‘DLBCL’, exhibiting characteristic biological features and clinical behaviour. However, information on RD-associated DLBCL is limited.MethodsWe searched the V.A. Nasonova Research Institute of Rheumatology (Russia) database from 1996 to 2021 for patients with RDs and coexisting DLBCL. Prognostic factors including the International Prognostic Index (IPI), bulk disease and c-MYC/8q24 gene rearrangements were analysed. Furthermore, we stratified DLBCLs as germinal centre B-cell (GCB) subtype and non-GCB subtype based on Hans’ immunohistochemical algorithm and also examined Epstein-Barr virus (EBV) status.ResultsTwenty-seven patients with RD-associated DLBCL were identified. Twenty patients had primary Sjogren’s syndrome, three had systemic lupus erythematosus, two had rheumatoid arthritis and two had systemic sclerosis. Secondary Sjogren’s syndrome was found in four patients. The median age at the time of diagnosis of DLBCL was 59 years with a female predominance (26:1). Based on IPI, 16 patients were assigned to the intermediate-high and high-risk groups. Bulk disease was detected in 29% of patients. Of the 20 examined cases, 4 (20%) were classified as the GCB subtype and 16 (80%) were classified as the non-GCB subtype. EBV was detected in 2 of the 21 tested cases (10%), and the c-MYC/8q24 gene rearrangement was not found in any of the 19 examined cases. After the lymphoma diagnosis, the median overall survival (OS) was 10 months (range: 0–238 months).ConclusionsExcept for the more common non-GCB subtype, we did not identify any other prognostic factor that could influence the prognosis of patients with RD-associated DLBCL. We believe that short OS in our patients was predominantly associated with decreased tolerance to lymphoma treatment.

A Rare Case of a Diffuse Large B-Cell Lymphoma (DLBCL) arising From The Parotid Gland In a Patient With Sjogren’s Syndrome

2016 ◽  
Vol 6 (1) ◽  
pp. 26-27
Author(s):  
Suresh Babu Mallekavu Chikkadasappa ◽  
Govind Babu Kanakasetty ◽  
Rajeev Lakkavalli Krishnappa ◽  
Suparna Ajit Rao
Keyword(s):  
Parotid Gland ◽  
B Cell ◽  
Rare Case ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Large B Cell Lymphoma ◽  
Large B Cell ◽  
Sjögren‘S Syndrome

scholarly journals Receptor tyrosine kinases MET and RON as prognostic factors in diffuse large B-cell lymphoma patients receiving R-CHOP

2013 ◽  
Vol 104 (9) ◽  
pp. 1245-1251 ◽  
Author(s):  
Young Wha Koh ◽  
Hee Sang Hwang ◽  
Se Jin Jung ◽  
Chansik Park ◽  
Dok Hyun Yoon ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
B Cell ◽  
Tyrosine Kinases ◽  
Receptor Tyrosine Kinases ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals C-MYC Aberrations as Prognostic Factors in Diffuse Large B-cell Lymphoma: A Meta-Analysis of Epidemiological Studies

PLoS ONE ◽  
2014 ◽  
Vol 9 (4) ◽  
pp. e95020 ◽  
Author(s):  
Kuangguo Zhou ◽  
Danmei Xu ◽  
Yang Cao ◽  
Jue Wang ◽  
Yunfan Yang ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
B Cell ◽  
Cell Lymphoma ◽  
Meta Analysis ◽  
B Cell Lymphoma ◽  
Epidemiological Studies ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Nodal marginal zone B-cell lymphoma associated with Sjögren's syndrome: A report of three cases

2007 ◽  
Vol 48 (6) ◽  
pp. 1222-1224 ◽  
Author(s):  
Masaru Kojima ◽  
Norihumi Tsukamoto ◽  
Yuri Miyazawa ◽  
Misa Iijima ◽  
Kazuhiko Shimizu ◽  
...  
Keyword(s):  
B Cell ◽  
Sjögren’S Syndrome ◽  
Marginal Zone ◽  
Sjögren's Syndrome ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Sjögren‘S Syndrome

scholarly journals New nomograms based on treatment outcome and prognostic factors for patients with spinal diffuse large B-cell lymphoma: A population‐based study

2020 ◽  
Author(s):  
Ben Wang ◽  
Lijie Chen ◽  
Boda Chen ◽  
Chenglong Xie ◽  
Zhenxuan Shao ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Treatment Method ◽  
Population Based ◽  
Cancer Specific Survival ◽  
Internal Validation ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Abstract Background: Spinal diffuse large B-cell lymphoma (DLBCL) was a rare and malignant tumor, while few studies researched the prognostic factors. The prognostic factors which might have impacts on spinal DLBCL was not clear. Although chemotherapy was recognized as an optimal treatment method, but the curative effect of radiotherapy and surgery were controversial. Methods: The records of patients with spinal DLBCL were selected from the SEER database from 1991 to 2016. The incidence obtained by database was analyzed by Joinpoint Regression Program. The optimal cut-off values of age and year of diagnosis were identified by X-tail program. Univariate and multivariate survival analysis were calculated to identify independent prognostic factors. Prognostic factors were included to predict the survival possibility compared with 5 years of overall (OS) and cancer-specific survival (CSS) via the new nomograms. Results: A total of 917 patients were enrolled. Age, year of diagnosis and chemotherapy were demonstrated as independent prognostic factors for CSS and OS, and primary site was another independent prognostic factor for CSS. However, radiotherapy and surgery might be ineffective in survival. All factors were included to generate the nomograms for CSS and OS. The concordance indices (C-index) for internal validation of OS and CSS prediction were 0.697 (95%CI: 0.662-0.732) and 0.709 (95%CI: 0.692- 0.727) respectively. Conclusions: Age and year of diagnosis are closely associated with the prognosis of spinal DLBCL, and chemotherapy is an ideal treatment modality. The new nomogram is a favourable tool to evaluate the survival possibility, and is benefit for the oncologist to make clinical decisions.

scholarly journals Osteopontin expression and its relationship with prognostic factors in diffuse large B-cell lymphoma

2019 ◽  
Vol 11 (3) ◽  
Author(s):  
Gilberto Barranco ◽  
Edith Fernández ◽  
Silvia Rivas ◽  
Roxana Quezada ◽  
Dolores Nava ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
B Cell ◽  
Germinal Center ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Cox Proportional Hazards ◽  
Biological Behavior ◽  
Large B Cell Lymphoma ◽  
The Impact ◽  
Large B Cell

The aim of this study is to explore the expression of osteopontin (OPN) and its relationship with prognostic factors and survival in diffuse large B cell lymphoma (DLBCL). A tissue microarray was performed for immunohistochemical evaluation. Contingency tables were analyzed for trends; chi-square test was used to determine differences between groups. Univariate and multivariate Cox proportional hazards-regression analyses were performed to evaluate the impact of prognostic factors on survival. Expression of OPN was observed in 28%. It was different in non-germinal center DLBCL (P=0.04). The mean overall survival (OS) was lower in patients with positive OPN expression (19.762; CI 95% 14.269-25.255) it was not significant (P=0.123). It is not possible to establish a clear relationship between the expression by immunohistochemistry of osteopontin and a poor prognosis but it would be important to complement the analysis with other techniques as PCR or NGS that allow us to assess the influence of the isoforms and post-translational modifications of OPN on the biological behavior of DLBCL. Our findings indicate that OPN expression could be associated with a more aggressive variant of lymphoma: non-germinal center DLBCL.

Sign in / Sign up

Export Citation Format

Share Document